Merck: A Dividend Growth Stock Worth Considering
Merck reported positive quarterly earnings with 6.7% year-over-year revenue growth and improved operating margin. The company generated strong leveraged free cash flow and reduced financial leverag...
US FDA panel votes against Merck's chronic cough drug
The U.S. health regulator's advisers on Friday did not recommend Merck's drug for the treatment of chronic cough.
Merck (MRK) Gets FDA Nod for Keytruda Expansion in Gastric Cancer
Following this approval, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers. Overall, the drug is approved for 38 indications in the country.
Merck's Keytruda combo wins FDA approval for gastric cancer
Merck & Co Inc (NYSE:MRK) announced on Thursday that its anti-PD-1 therapy Keytruda in combination with chemotherapy has been approved by the U.S. Food and Drug Administration (FDA) for gastric can...
Merck's Keytruda gets approval to treat certain types of gastric cancer
Merck MRK, +0.63% said late Thursday that the Food and Drug Administration has approved its star cancer drug Keytruda as treatment for some adult gastrointestinal cancers, alongside chemotherapy. A...
US FDA staff flags concerns on Merck's chronic cough drug
U.S. Food and Drug Administration's reviewers on Wednesday flagged concerns that data on Merck's chronic cough drug might not be sufficient to prove meaningful benefit, according to documents relea...
Nike, Merck Among 13 Companies To Announce Annual Dividend Increases In Second Half Of November
Investors were rewarded with 10%+ dividend increases from Snap-on Tools and ADP in the first half of November. Other companies that rewarded investors in the first two weeks of the month were Emers...
Merck & Co., Inc. (MRK) Presents at UBS BioPharma Conference (Transcript)
Merck & Co., Inc. (NYSE:MRK ) UBS BioPharma Conference November 8, 2023 12:00 PM ET Company Participants Jannie Oosthuizen - President, U.S. Human Health Business, Merck Conference Call Participant...
Merck's drug Keytruda recommended for EU approval for biliary tract cancer
Merck & Co Inc (NYSE:MRK) announced Friday that its drug Keytruda has been backed by the European Medicines Agency's Committee for Medicinal Products in Human Use (CHMP) for use in certain patients...
Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now?
Merck and Daiichi Sankyo just signed a multibillion-dollar drug collaboration. The pair will work to develop three medicines to eventually replace Keytruda.
BMO Capital upgrades Merck to 'outperform'
BMO has upgraded Merck to outperform from market perform.
Analyst: Merck Stock Could Jump 25%
BMO Capital upgraded shares of pharmaceutical company Merck & Co., Inc. (NYSE:MRK) to "outperform" from "market perform" and hiked its price target to $132.
Merck's Profit Beats Estimates on Sales of Its Cancer, COVID-19 Drugs and HPV Shot
Merck (MRK) posted better-than-expected results on strong sales of its popular Keytruda cancer drug and HPV vaccine Gardasil, as well as a jump in demand for its Lagevrio COVID-19 treatment.
Merck & Co., Inc. (MRK) Q3 2023 Earnings Call Transcript
Merck & Co., Inc. (NYSE:MRK ) Q3 2023 Earnings Conference Call October 26, 2023 9:00 AM ET Company Participants Peter Dannenbaum - Vice President, Investor Relations Rob Davis - Chairman and CEO Ca...
Merck (MRK) Q3 Earnings Top Estimates, COVID Drug Boosts Sales
Merck (MRK) beats Q3 estimates for earnings and sales. It raises its 2023 guidance.
Related Companies